Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

FDA Grants Orphan Drug Designation for Mithridion’s MCD-386CR to Treat Progressive Supranuclear Palsy

May 8, 2011 By Bio-Medicine.Org

MADISON, Wis., May 9, 2011 /PRNewswire/ — Mithridion, Inc., a
privately-owned clinical stage drug development company focusing on
serious Central Nervous System (CNS) disorders, announces that the
U.S. Food and Drug Administration (FDA) has awarded Orphan Drug
designation for MCD-386CR, its lead drug candidate, for the
treatment of Progressive Supranuclear Palsy (PSP).

Orphan status entitles Mithridion to seven years of market
exclusivity upon approval of MCD-386 for treating PSP, and to apply
for grant funding to contribute to clinical trial costs, tax
credits, and a waiver of certain FDA fees.  Orphan status is
intended to encourage the development of drugs for diseases
affecting fewer than 200,000 persons in the USA.

PSP is a progressive brain disease in which neurons degenerate
in regions of the brain vital for eye movements, balance, walking,
speech, and cognition.  Cognitive impairment typically
involves slowed thinking, and difficulties with reasoning,
planning, and shifting between tasks, caused by dysfunction of the
brain’s executive functions.  This has been called
“dysexecutive  syndrome.”

“Orphan status will help us immeasurably to bring together the
resources and support needed to evaluate MCD-386CR in this rare but
important disease, and indeed in other devastating brain diseases
for which there are no current therapies,” said Trevor M. Twose,
Ph.D., the company’s Chief Executive. “Based on results in
preclinical studies, we believe MCD-386CR potentially will help
restore cognition, so vital to human functioning, and potentially
could treat the underlying processes causing the degeneration of
neurons in PSP.”

As a part of its recently-articulated strategy, Mithridion is
actively exploring opportunities to develop its drug candidates in
niche market opportunities in serious CNS or brain disorders, in
addition to more common diseases, such as Alzheimer’s disease and
schizophrenia.  Several promisi

‘/>”/>

SOURCE

Related Articles Read More >

DeepWell Digital Therapeutics Mike Wilson Ryan Douglas
How DeepWell is developing video games as tools for treating medical conditions
A woman with a small, handheld device in her lap with tubes that look like earphones plugged into her ears.
Ear-puffing device for migraine treatment wins FDA breakthrough designation
Abbott
Abbott launches upgraded digital health app for neurostimulation
Catheter delivery could enable better brain implants: Synchron’s neuroscience chief explains how

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech